keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg Clearance

keyword
https://www.readbyqxmd.com/read/29783985/the-doses-of-plasmid-backbone-plays-a-major-role-in-determining-the-hbv-clearance-in-hydrodynamic-injection-mouse-model
#1
Xian Wang, Jianmin Zhu, Yong Zhang, Yue Li, Tai Ma, Qun Li, Jiegou Xu, Long Xu
BACKGROUND: Hepatitis B virus (HBV) chronically infects approximately 350 million people worldwide, causing a major risk of liver disease and hepatocellular carcinoma (HCC). Many mouse models have been tried to establish HBV infection through injection with various HBV-containing plasmids. However, it is not well understood that different plasmids, all of which contain the similar HBV genome, even the same plasmids with different dose, results in opposite immune responses toward HBV. METHODS: In this study, we investigated the role of HBV-containing plasmid backbones and the HBcAg in determining the HBV persistence...
May 21, 2018: Virology Journal
https://www.readbyqxmd.com/read/29720863/hepatitis-b-and-c-coinfection-in-a-real-life-setting-viral-interactions-and-treatment-issues
#2
Nikolaos Papadopoulos, Maria Papavdi, Anna Pavlidou, Dimitris Konstantinou, Hariklia Kranidioti, George Kontos, John Koskinas, George V Papatheodoridis, Spilios Manolakopoulos, Melanie Deutsch
Background: Only limited data concerning hepatitis B (HBV) and C viruses (HCV) coinfection are available. Direct-acting antivirals (DAAs) may be more effective for HCV clearance than interferon (IFN)-based regimens with a risk of HBV reactivation. Methods: We retrospectively enrolled 40 HBV/HCV-coinfected patients to evaluate their clinical profile and treatment outcomes. Results: Chronic dual infection was present in 25/40 (62.5%) patients, acute HCV superinfection in 5/40 (12...
May 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29707079/prevalence-of-hepatitis-b-reactivation-among-chinese-individuals-with-chronic-hepatitis-c-treated-with-pan-oral-direct-acting-antivirals
#3
Shou-Wu Lee, Teng-Yu Lee, Sheng-Shun Yang, Yen-Chun Peng, Hong-Zen Yeh, Chi-Sen Chang
Background: Clearance of hepatitis C virus (HCV) has been reported to induce the reactivation of hepatitis B virus (HBV). The aim of this study was to investigate the rate of HBV reactivation in HCV-infected Chinese patients who received treatment with pan-oral direct-acting antivirals (DAAs). Methods: Data from HCV subjects receiving oral DAA therapy were retrospectively collected from October 2015 to May 2017. Patients who were seropositive for HBsAg or anti-HBc were enrolled...
April 2018: Gastroenterology Research
https://www.readbyqxmd.com/read/29689122/efficacy-and-safety-of-peginterferon-alfa-2a-40kd-in-children-with-chronic-hepatitis-b-the-peg-b-active-study
#4
Stefan Wirth, Hongfei Zhang, Winita Hardikar, Kathleen B Schwarz, Etienne Sokal, Weibo Yang, Huimin Fan, Vyacheslav Morozov, Qing Mao, Hong Deng, Yang Huang, Lei Yang, Nicolas Frey, Clare Nasmyth-Miller, Vedran Pavlovic, Cynthia Wat
Children with chronic hepatitis B (CHB) represent an area of unmet medical need, due to increased lifetime risk of CHB sequelae and limited therapeutic options compared with adult CHB patients. The PEG-B-ACTIVE (NCT01519960) phase III study evaluated peginterferon (PegIFN) alfa-2a treatment in children aged 3 to <18 years with CHB. A total of 161 hepatitis B e antigen (HBeAg)-positive immune-active patients without advanced fibrosis/cirrhosis were randomized (2:1) to PegIFN alfa-2a (Group A, n = 101) or no treatment (Group B, n = 50); patients with advanced fibrosis were assigned to PegIFN alfa-2a (Group C, n = 10)...
April 24, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29685146/pretreatment-microrna-levels-can-predict-hbsag-clearance-in-chb-patients-treated-with-pegylated-interferon-%C3%AE-2a
#5
Yanlin Yang, Ming Liu, Ying Deng, Yan Guo, Xuqing Zhang, Dedong Xiang, Li Jiang, Zhonglan You, Yi Wu, Maoshi Li, Qing Mao
BACKGROUND: To investigate the predictive capability of microRNAs (miRNAs) prior treatment for HBsAg clearance in chronic hepatitis B (CHB) treated with pegylated interferon α-2a (PEG-IFNα-2a). METHODS: The treatment effect was determined by HBsAg clearance and subjects were classified into HBsAg clearance group and non HBsAg clearance group. Differential miRNAs expression in peripheral blood mononuclear cells (PBMC) was screened using microarrays in an identification cohort (n = 20) and validated by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in a confirmation cohort (n = 47)...
April 23, 2018: Virology Journal
https://www.readbyqxmd.com/read/29675010/an-overview-of-hepatitis-b-virus-surface-antigen-secretion-inhibitors
#6
REVIEW
Alireza Mohebbi, Nazanin Lorestani, Alireza Tahamtan, Niki L Kargar, Alijan Tabarraei
Current anti-hepatitis B virus (HBV) regimen do not meet ideal result due to emerging resistance strains, cytotoxicity, and unfavorable adverse effects. In chronic HBV infection, high rates of sub-viral particles (SVPs) bearing HBV surface antigen (HBsAg) is a major obstacle regarding to raise effective immune responses and subsequently virus clearance. Development of potent HBsAg secretion inhibitors would provide a better insight into HBV immunopathogenesis and therapy. Investigating new non-toxic HBsAg secretion inhibitors targeting either viral or cellular factors could restore the immune response to remove virally infected hepatocytes after inhibiting SVPs...
2018: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29625837/hbsag-stimulates-nkg2d-receptor-expression-on-natural-killer-cells-and-inhibits-hepatitis-c-virus-replication
#7
Xiao-Xiao Wang, Xiao-Ben Pan, Jin-Chao Han, Xu Cong, Qian Jin, Xiang-Sha Kong, Lai Wei, Bo Feng
BACKGROUND: Higher hepatitis B surface antigen (HBsAg) facilitates hepatitis C virus (HCV) clearance in patients with hepatitis B virus (HBV)/HCV co-infection. We investigated the effect of exogenous HBsAg on the inhibition of HCV replication mediated by natural killer (NK) cells. METHODS: After isolated from peripheral blood of 42 chronic hepatitis B (CHB) patients and 16 healthy individuals, NK cells were co-cultured with HCV-infected Huh7 cells, respectively, with or without HBsAg...
March 26, 2018: Hepatobiliary & Pancreatic Diseases International: HBPD INT
https://www.readbyqxmd.com/read/29606938/spontaneous-hepatitis-b-seroclearance-upon-development-of-hepatocellular-carcinoma
#8
Sara Naimimohasses, Omar El Sherif, Mohammad Ashfaq, Niamh Nolan, Masood Iqbal, Susan McKiernan, Suzanne Norris
The spontaneous seroclearance of hepatitis B upon development of a hepatocellular carcinoma (HCC) is extremely rare. To date, there has been one published case series reporting hepatitis B seroconversion following HCC resection. We describe two novel cases of spontaneous hepatitis B seroclearance following the development of HCC, prior to resection. Following resection, specimens were HBsAg- and HBcAg-negative in both tumor and peritumor tissues. Although the precise mechanism of this is poorly understood, nonuniform integration of hepatitis B virus DNA within the liver could lead to selective tumorigenesis of HBsAg-producing cells, explaining the observed clearance of serum HBsAg with the development of HCC...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29602711/tenofovir-disoproxil-fumarate-co-administered-with-lopinavir-ritonavir-is-strongly-associated-with-tubular-damage-and-chronic-kidney-disease
#9
Daisuke Mizushima, Dung Thi Hoai Nguyen, Dung Thi Nguyen, Shoko Matsumoto, Junko Tanuma, Hiroyuki Gatanaga, Nguyen Vu Trung, Nguyen van Kinh, Shinichi Oka
BACKGROUD: With expanding antiretroviral therapy (ART) in a resource-limited setting, the use of second line ART with ritonavir boosted lopinavir (LPV/r) is increasing. However, little is known regarding the renal safety of tenofovir (TDF) co-administered with LPV/r. METHODS: In total 1382 HIV-infected patients were enrolled and data were recorded twice (October 2014 and 2015) in Vietnam. Tubular dysfunction (TD) was defined as urinary beta 2 microglobulin (β2MG) > 1000 μg/L at both timepoints or increase in β2MG by > 2000 μg/L...
March 27, 2018: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/29596494/high-rates-of-chronic-hbv-genotype-e-infection-in-a-group-of-migrants-in-italy-from-west-africa-virological-characteristics-associated-with-poor-immune-clearance
#10
Vincenzo Malagnino, Romina Salpini, Gaetano Maffongelli, Arianna Battisti, Lavinia Fabeni, Lorenzo Piermatteo, Luna Colagrossi, Vanessa Fini, Alessandra Ricciardi, Cesare Sarrecchia, Carlo Federico Perno, Massimo Andreoni, Valentina Svicher, Loredana Sarmati
Hepatitis B virus (HBV) genotype E almost exclusively occurs in African people, and its presence is more commonly associated with the development of chronic HBV (CHB) infection. Moreover, an epidemiological link has been found between the distribution of HBV genotype E infection and African countries with high incidences of hepatocellular carcinoma. As part of a programme for the health assessment of migrants, we evaluated 358 young African subjects for HBV infection; 58.1% (208/358) were positive for an HBV marker, and 54 (25...
2018: PloS One
https://www.readbyqxmd.com/read/29577515/impact-of-previous-hepatitis-b-infection-on-the-clinical-outcomes-from-chronic-hepatitis-c-a-population-level-analysis
#11
H Wang, R Swann, E Thomas, H A Innes, H Valerio, P C Hayes, S Allen, S T Barclay, D Wilks, R Fox, D Bhattacharyya, N Kennedy, J Morris, A Fraser, A J Stanley, R Gunson, P G Mclntyre, A Hunt, S J Hutchinson, P R Mills, J F Dillon
Chronic coinfection with hepatitis C virus (HCV) and hepatitis B virus (HBV) is associated with adverse liver outcomes. The clinical impact of previous HBV infection on liver disease in HCV infection is unknown. We aimed at determining any association of previous HBV infection with liver outcomes using antibodies to the hepatitis B core antigen (HBcAb) positivity as a marker of exposure. The Scottish Hepatitis C Clinical Database containing data for all patients attending HCV clinics in participating health boards was linked to the HBV diagnostic registry and mortality data from Information Services Division, Scotland...
March 25, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29577360/systematic-review-with-meta-analysis-combination-treatment-of-regimens-based-on-pegylated-interferon-for-chronic-hepatitis-b-focusing-on-hepatitis-b-surface-antigen-clearance
#12
REVIEW
K Qiu, B Liu, S-Y Li, H Li, Z-W Chen, A-R Luo, M-L Peng, H Ren, P Hu
BACKGROUND: The seroclearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) is considered to be associated with favourable clinical outcomes. AIMS: This meta-analysis was performed to establish the proportion of HBsAg loss rates among CHB patients who received combination treatment based on pegylated interferon (PegIFN). Four combination strategies have been studied with the aim of improving HBsAg loss: "de novo," "NA-experienced," "switch-to" and "add-on...
March 26, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29544722/dysregulated-response-of-follicular-helper-t-cells-to-hepatitis-b-surface-antigen-promotes-hbv-persistence-in-mice-and-associates-with-outcomes-of-patients
#13
Xiaowen Wang, Qingyang Dong, Qian Li, Yuanyuan Li, Dianyuan Zhao, Jinjie Sun, Junliang Fu, Fanping Meng, Hu Lin, Junjie Luan, Biao Liu, Min Wang, Fusheng Wang, Fuchu He, Li Tang
BACKGROUND & AIMS: Production of neutralizing antibodies against hepatitis B surface antigen (HBsAg) is dysregulated in patients with persistent hepatitis B virus (HBV) infection. We investigated mechanisms by which this immune response to the virus is disrupted and whether it can be restored to promote clearance of HBV. METHODS: Immune-competent C57BL/6N and C57BL/6J, as well as mice deficient in follicular helper T cells (Tfh-cell-deficient), B cells, or Foxp3+ T-regulatory cells (Treg cell deficient), were given hydrodynamic injections of pAAV/HBV1...
March 12, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29541698/adcc-mediated-cd56-dim-nk-cell-responses-are-associated-with-early-hbsag-clearance-in-acute-hbv-infection
#14
Wen-Han Yu, Cormac Cosgrove, Christoph T Berger, Patrick C Cheney, Marina Krykbaeva, Arthur Y Kim, Lia Lewis-Ximenez, Georg M Lauer, Galit Alter
Background: Hepatitis B virus (HBV) affects up to 400 million people worldwide and accounts for approximately one million deaths per year from liver pathologies. Current treatment regimens are effective in suppressing viremia but usually have to be taken indefinitely, warranting research into new therapeutic approaches. Acute HBV infection in adults almost universally results in resolution of viremia, with the exception of immunocompromised persons, suggesting that the immune response can functionally cure or even eradicate HBV infection...
2018: Pathogens & Immunity
https://www.readbyqxmd.com/read/29484170/correlation-between-hepatic-human-males-absent-on-the-first-hmof-and-viral-persistence-in-chronic-hepatitis-b-patients
#15
Liwen Chen, Chuanwu Zhu, Fengdi Li, Yun Wang, Rebecca Bao, Zhujun Cao, Xiaogang Xiang, Lei Yan, Lanyi Lin, Gangde Zhao, Qing Xie, Shisan Bao, Hui Wang
Background: Chronic hepatitis B (CHB) remains a global health dilemma with high morbidity and mortality. Human males absent on the first (hMOF) (a histone acetyltransferase) is responsible for DNA damage repair, tumorigenesis and cell cycle regulation. Persistence of HBV DNA contributes to cirrhosis and hepatocellular carcinoma (HCC) in CHB patients. Histone acetyltransferase enhances HBV replication, however the precise underlying mechanism of hMOF in HBV replication in CHB patients remains to be explored...
2018: Cell & Bioscience
https://www.readbyqxmd.com/read/29471567/targeting-hepatitis-d
#16
Mario Rizzetto
New therapeutic strategies to treat chronic hepatitis D are directed to deprive the hepatitis D virus (HDV) of functions necessary to complete its life cycle that are provided by the hepatitis B virus (HBV) and by the host. Current options are (1) the block by the synthetic peptide Myrcludex B of HBV surface antigen (HBsAg) entry into cells through the inhibition of the sodium taurocholate cotransporting receptor; (2) the inhibition with lonafarnib of the farnesylation of the large HD antigen, required for virion assembly; (3) the presumed reduction by the nucleic acid polymer REP 2139 of the release of the HBsAg and subviral HBV particles necessary for HD virion morphogenesis...
February 2018: Seminars in Liver Disease
https://www.readbyqxmd.com/read/29469040/long-term-follow-up-and-quantitative-hepatitis-b-surface-antigen-monitoring-in-north-american-chronic-hbv-carriers
#17
Conar R O'Neil, Stephen E Congly, M Sarah Rose, Samuel S Lee, Meredith A Borman, Carmen L Charlton, Carla Osiowy, Mark G Swain, Kelly W Burak, Carla S Coffin
INTRODUCTION: Quantitative hepatitis B surface antigen (qHBsAg) combined with HBV DNA may be useful for predicting chronic hepatitis B (CHB) activity and nucleoside analogue (NA) response. MATERIAL AND METHODS: In this retrospective cohort study we evaluated qHBsAg levels according to CHB disease phase and among patients on treatment. Random effect logistic regression analysis was used to analyze qHBsAg change with time in the NA-treated cohort. RESULTS: 545 CHB carriers [56% M, median age 48 y (IQR 38-59), 73% Asian] had qHBsAg testing...
March 1, 2018: Annals of Hepatology
https://www.readbyqxmd.com/read/29452204/antiviral-therapy-in-hepatitis-b-virus-infected-children-with-immune-tolerant-characteristics-a-pilot-open-label-randomized-study
#18
Shishu Zhu, Hongfei Zhang, Yi Dong, Limin Wang, Zhiqiang Xu, Weiwei Liu, Yu Gan, Hongmei Tang, Dawei Chen, Fuchuan Wang, Pan Zhao
BACKGROUND & AIM: Chronic infection with hepatitis B virus (HBV) in children is a serious health problem worldwide. How to treat children with immune-tolerant chronic hepatitis B infection, commonly characterized by hepatitis B e antigen (HBeAg) positivity, high viral load, normal or mildly elevated alanine aminotransferase and no or minimal inflammation in liver histology, remains unresolved. This trial aims to study the benefits of antiviral therapy in children with these characteristics...
February 13, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29438098/sustained-antiviral-effects-and-clearance-of-hepatitis-surface-antigen-after-combination-therapy-with-entecavir-and-pegylated-interferon-in-chronic-hepatitis-b
#19
Satoru Hagiwara, Naoshi Nishida, Tomohiro Watanabe, Hiroshi Ida, Toshiharu Sakurai, Kazuomi Ueshima, Masahiro Takita, Yoriaki Komeda, Norihiro Nishijima, Yukio Osaki, Masatoshi Kudo
BACKGROUND: Although the efficacy of combination therapy with lamivudine or tenofovir and pegylated-interferon (Peg-IFN) has been reported in patients with chronic hepatitis B (CHB), the long-term effect of the combination based on the observation of clinical course remains to be clarified. We previously reported the efficacy of combination therapy with entecavir (ETV) and Peg-IFN. Here, we investigated the long-term effect of this combination in patients with CHB. METHODS: We administered both ETV and Peg-IFN α-2a or -2b simultaneously to 26 patients with hepatitis B virus genotype C infection...
February 13, 2018: Antiviral Therapy
https://www.readbyqxmd.com/read/29427495/hepatitis-b-who-and-when-to-treat
#20
REVIEW
Jiannis Vlachogiannakos, George V Papatheodoridis
As current treatment options almost never achieve eradication of hepatitis B virus (HBV), the most realistic goal for HBV treatment is persistent inhibition of viral replication and ALT normalization. Thus, the decision to start treatment should be based on careful patient selection and individualized decisions. Treatment is generally indicated in chronic hepatitis B patients with HBV DNA >2000 IU/mL, elevated ALT and/or at least moderate histological lesions, while all patients with cirrhosis and detectable HBV DNA should be treated...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
42773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"